Today's Analyst Stock Ratings | Upgrades, Downgrades

SPY767.50+0.13%QQQ719.02+0.09%BTC/USD—DIA519.52+0.12%GLD378.71−0.26%TLT79.52+0.08%

							Get Alert
Oct 8, 2026	JAZZJazz Pharmaceuticals	$208.43	42.01%	Leonid TimashevRBC Capital 64%	296 299	Previous Outperform Current Outperform	Get Alert
Oct 7, 2026	JAZZJazz Pharmaceuticals	$208.43	37.22%	Gregory RenzaTruist Securities 61%	281 286	Previous Buy Current Buy	Get Alert
Sep 30, 2026	JAZZJazz Pharmaceuticals	$208.43	55.93%	Geoff MeachamCitigroup 73%	325	Previous Initiates Current Buy	Get Alert
Sep 24, 2026	JAZZJazz Pharmaceuticals	$208.43	61.68%	Andrea NewkirkGoldman Sachs 63%	337	Previous Current Buy	Get Alert
Sep 11, 2026	JAZZJazz Pharmaceuticals	$208.43	61.68%	Ashwani VermaUBS 63%	315 337	Previous Buy Current Buy	Get Alert
Sep 10, 2026	JAZZJazz Pharmaceuticals	$208.43	30.02%	Etzer DaroutBarclays 67%	270 271	Previous Overweight Current Overweight	Get Alert
Aug 26, 2026	JAZZJazz Pharmaceuticals	$208.43	43.93%	David HoangDeutsche Bank 58%	287 300	Previous Buy Current Buy	Get Alert
Aug 26, 2026	JAZZJazz Pharmaceuticals	$208.43	54.49%	Jeffrey HungMorgan Stanley 71%	283 322	Previous Overweight Current Overweight	Get Alert
Aug 26, 2026	JAZZJazz Pharmaceuticals	$208.43	34.82%	Gregory RenzaTruist Securities 61%	264 281	Previous Buy Current Buy	Get Alert
Aug 26, 2026	JAZZJazz Pharmaceuticals	$208.43	48.73%	Ami FadiaNeedham 73%	292 310	Previous Buy Current Buy	Get Alert
Aug 11, 2026	JAZZJazz Pharmaceuticals	$208.43	35.78%	Jeffrey HungMorgan Stanley 71%	280 283	Previous Overweight Current Overweight	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	32.42%	Jessica FyeJP Morgan 64%	265 276	Previous Overweight Current Overweight	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	26.66%	Gregory RenzaTruist Securities 61%	254 264	Previous Buy Current Buy	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	43.93%	Joseph ThomeTD Cowen 36%	275 300	Previous Buy Current Buy	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	48.73%	David AmsellemPiper Sandler 79%	301 310	Previous Overweight Current Overweight	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	43.93%	Mohit BansalWells Fargo 71%	285 300	Previous Overweight Current Overweight	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	34.34%	Jeffrey HungMorgan Stanley 71%	245 280	Previous Overweight Current Overweight	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	40.09%	Ami FadiaNeedham 73%	282 292	Previous Buy Current Buy	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	29.54%	Etzer DaroutBarclays 67%	260 270	Previous Overweight Current Overweight	Get Alert
Aug 4, 2026	JAZZJazz Pharmaceuticals	$208.43	34.34%	Joel BeattyBaird 75%	252 280	Previous Outperform Current Outperform	Get Alert
Jul 20, 2026	JAZZJazz Pharmaceuticals	$208.43	35.3%	Ami FadiaNeedham 73%	255 282	Previous Buy Current Buy	Get Alert
Jul 17, 2026	JAZZJazz Pharmaceuticals	$208.43	39.14%	Gary NachmanCanaccord Genuity 59%	290	Previous Initiates Current Buy	Get Alert
Jul 14, 2026	JAZZJazz Pharmaceuticals	$208.43	36.74%	Mohit BansalWells Fargo 71%	265 285	Previous Overweight Current Overweight	Get Alert
Jul 14, 2026	JAZZJazz Pharmaceuticals	$208.43	24.74%	Etzer DaroutBarclays 67%	253 260	Previous Overweight Current Overweight	Get Alert
Jul 9, 2026	JAZZJazz Pharmaceuticals	$208.43	29.54%	Gregg GilbertDeutsche Bank 59%	250 270	Previous Buy Current Buy	Get Alert
Jul 7, 2026	JAZZJazz Pharmaceuticals	$208.43	21.86%	Gregory RenzaTruist Securities 61%	254 256	Previous Buy Current Buy	Get Alert
Jun 10, 2026	JAZZJazz Pharmaceuticals	$208.43	47.29%	Jason GerberryB of A Securities 64%	281 307	Previous Buy Current Buy	Get Alert
May 27, 2026	JAZZJazz Pharmaceuticals	$208.43	21.38%	Etzer DaroutBarclays 67%	234 253	Previous Overweight Current Overweight	Get Alert
May 22, 2026	JAZZJazz Pharmaceuticals	$208.43	9.87%	Jeffrey WalchBernstein 33%	229	Previous Initiates Current Market Perform	Get Alert
May 22, 2026	JAZZJazz Pharmaceuticals	$208.43	44.41%	David AmsellemPiper Sandler 79%	232 301	Previous Overweight Current Overweight	Get Alert
May 19, 2026	JAZZJazz Pharmaceuticals	$208.43	47.29%	Ashwani VermaUBS 63%	188 307	Previous Neutral Current Buy	Get Alert
May 6, 2026	JAZZJazz Pharmaceuticals	$208.43	31.94%	Joseph ThomeTD Cowen 36%	220 275	Previous Buy Current Buy	Get Alert
May 6, 2026	JAZZJazz Pharmaceuticals	$208.43	23.78%	Leonid TimashevRBC Capital 64%	195 258	Previous Outperform Current Outperform	Get Alert
May 6, 2026	JAZZJazz Pharmaceuticals	$208.43	12.27%	Etzer DaroutBarclays 67%	225 234	Previous Overweight Current Overweight	Get Alert
May 6, 2026	JAZZJazz Pharmaceuticals	$208.43	27.14%	Mohit BansalWells Fargo 71%	250 265	Previous Overweight Current Overweight	Get Alert
Apr 24, 2026	JAZZJazz Pharmaceuticals	$208.43	22.34%	Ami FadiaNeedham 73%	235 255	Previous Buy Current Buy	Get Alert
Apr 22, 2026	JAZZJazz Pharmaceuticals	$208.43	7.95%	Marc GoodmanLeerink Partners 70%	215 225	Previous Outperform Current Outperform	Get Alert
Apr 20, 2026	JAZZJazz Pharmaceuticals	$208.43	7.95%	Etzer DaroutBarclays 67%	224 225	Previous Overweight Current Overweight	Get Alert
Mar 19, 2026	JAZZJazz Pharmaceuticals	$208.43	11.31%	David AmsellemPiper Sandler 79%	219 232	Previous Overweight Current Overweight	Get Alert
Feb 27, 2026	JAZZJazz Pharmaceuticals	$208.43	7.47%	Etzer DaroutBarclays 67%	224	Previous Initiates Current Overweight	Get Alert
Feb 25, 2026	JAZZJazz Pharmaceuticals	$208.43	-6.44%	Leonid TimashevRBC Capital 64%	191 195	Previous Outperform Current Outperform	Get Alert
Feb 25, 2026	JAZZJazz Pharmaceuticals	$208.43	8.43%	Jeffrey HungMorgan Stanley 71%	225 226	Previous Overweight Current Overweight	Get Alert
Feb 25, 2026	JAZZJazz Pharmaceuticals	$208.43	19.94%	Mohit BansalWells Fargo 71%	235 250	Previous Overweight Current Overweight	Get Alert
Feb 25, 2026	JAZZJazz Pharmaceuticals	$208.43	31.94%	Jason GerberryB of A Securities 64%	263 275	Previous Buy Current Buy	Get Alert
Jan 12, 2026	JAZZJazz Pharmaceuticals	$208.43	10.35%	Joon LeeTruist Securities 79%	220 230	Previous Buy Current Buy	Get Alert
Jan 12, 2026	JAZZJazz Pharmaceuticals	$208.43	12.75%	Ami FadiaNeedham 73%	210 235	Previous Buy Current Buy	Get Alert
Dec 10, 2025	JAZZJazz Pharmaceuticals	$208.43	5.07%	David AmsellemPiper Sandler 79%	147 219	Previous Overweight Current Overweight	Get Alert
Nov 24, 2025	JAZZJazz Pharmaceuticals	$208.43	-9.8%	Ashwani VermaUBS 63%	163 188	Previous Buy Current Neutral	Get Alert
Nov 18, 2025	JAZZJazz Pharmaceuticals	$208.43	12.75%	Mohit BansalWells Fargo 71%	170 235	Previous Overweight Current Overweight	Get Alert
Nov 18, 2025	JAZZJazz Pharmaceuticals	$208.43	0.27%	Joel BeattyBaird 75%	160 209	Previous Outperform Current Outperform	Get Alert
Nov 18, 2025	JAZZJazz Pharmaceuticals	$208.43	18.51%	Jason GerberryB of A Securities 64%	230 247	Previous Buy Current Buy	Get Alert
Nov 17, 2025	JAZZJazz Pharmaceuticals	$208.43	-6.92%	Leonid TimashevRBC Capital 64%	155 194	Previous Outperform Current Outperform	Get Alert
Nov 17, 2025	JAZZJazz Pharmaceuticals	$208.43	-1.65%	Jeffrey HungMorgan Stanley 71%	185 205	Previous Overweight Current Overweight	Get Alert
Nov 6, 2025	JAZZJazz Pharmaceuticals	$208.43	-25.63%	Leonid TimashevRBC Capital 64%	151 155	Previous Outperform Current Outperform	Get Alert
Oct 27, 2025	JAZZJazz Pharmaceuticals	$208.43	-4.52%	Jessica FyeJP Morgan 64%	199 204	Previous Overweight Current Overweight	Get Alert
Oct 20, 2025	JAZZJazz Pharmaceuticals	$208.43	-13.64%	Jeffrey HungMorgan Stanley 71%	167 180	Previous Overweight Current Overweight	Get Alert
Sep 24, 2025	JAZZJazz Pharmaceuticals	$208.43	-19.88%	Jeffrey HungMorgan Stanley 71%	163 167	Previous Overweight Current Overweight	Get Alert
Aug 29, 2025	JAZZJazz Pharmaceuticals	$208.43	-11.24%	Madhu KumarGoldman Sachs 72%	162 185	Previous Buy Current Buy	Get Alert
Aug 28, 2025	JAZZJazz Pharmaceuticals	$208.43	-1.65%	Joon LeeTruist Securities 79%	200 205	Previous Buy Current Buy	Get Alert
Aug 28, 2025	JAZZJazz Pharmaceuticals	$208.43	-21.8%	Jeffrey HungMorgan Stanley 71%	162 163	Previous Overweight Current Overweight	Get Alert
Aug 28, 2025	JAZZJazz Pharmaceuticals	$208.43	-27.55%	Leonid TimashevRBC Capital 64%	145 151	Previous Outperform Current Outperform	Get Alert
Aug 28, 2025	JAZZJazz Pharmaceuticals	$208.43	-3.08%	Ami FadiaNeedham 73%	202 202	Previous Buy Current Buy	Get Alert
Aug 20, 2025	JAZZJazz Pharmaceuticals	$208.43	-3.08%	Ami FadiaNeedham 73%	202 202	Previous Buy Current Buy	Get Alert
Aug 6, 2025	JAZZJazz Pharmaceuticals	$208.43	-22.28%	Jeffrey HungMorgan Stanley 71%	162 165	Previous Overweight Current Overweight	Get Alert
Jul 22, 2025	JAZZJazz Pharmaceuticals	$208.43	-20.84%	Jeffrey HungMorgan Stanley 71%	165 166	Previous Overweight Current Overweight	Get Alert
Jun 11, 2025	JAZZJazz Pharmaceuticals	$208.43	-3.08%	Ami FadiaNeedham 73%	202 202	Previous Buy Current Buy	Get Alert
Jun 3, 2025	JAZZJazz Pharmaceuticals	$208.43	-3.08%	Ami FadiaNeedham 73%	202 202	Previous Buy Current Buy	Get Alert
May 7, 2025	JAZZJazz Pharmaceuticals	$208.43	-25.63%	Joel BeattyBaird 75%	155 167	Previous Outperform Current Outperform	Get Alert
May 7, 2025	JAZZJazz Pharmaceuticals	$208.43	-17.48%	Gregory RenzaRBC Capital 61%	172 182	Previous Outperform Current Outperform	Get Alert
May 7, 2025	JAZZJazz Pharmaceuticals	$208.43	-29.47%	David AmsellemPiper Sandler 79%	147 176	Previous Overweight Current Overweight	Get Alert
May 7, 2025	JAZZJazz Pharmaceuticals	$208.43	-20.36%	Jeffrey HungMorgan Stanley 71%	166 183	Previous Overweight Current Overweight	Get Alert
May 7, 2025	JAZZJazz Pharmaceuticals	$208.43	-4.04%	Ami FadiaNeedham 73%	200 200	Previous Buy Current Buy	Get Alert
Apr 10, 2025	JAZZJazz Pharmaceuticals	$208.43	0.75%	Ami FadiaNeedham 73%	210 210	Previous Buy Current Buy	Get Alert
Mar 10, 2025	JAZZJazz Pharmaceuticals	$208.43	4.11%	Oren LivnatHC Wainwright & Co. 74%	200 217	Previous Buy Current Buy	Get Alert
Mar 7, 2025	JAZZJazz Pharmaceuticals	$208.43	-12.2%	Jeffrey HungMorgan Stanley 71%	175 183	Previous Current Overweight	Get Alert
Mar 7, 2025	JAZZJazz Pharmaceuticals	$208.43	-14.12%	Ashwani VermaUBS 63%	145 179	Previous Neutral Current Buy	Get Alert
Mar 6, 2025	JAZZJazz Pharmaceuticals	$208.43	10.35%	Gregory FraserTruist Securities 61%	220 230	Previous Buy Current Buy	Get Alert
Mar 5, 2025	JAZZJazz Pharmaceuticals	$208.43	0.75%	Ami FadiaNeedham 73%	210 210	Previous Buy Current Buy	Get Alert
Feb 27, 2025	JAZZJazz Pharmaceuticals	$208.43	-4.04%	Balaji PrasadBarclays 59%	190 200	Previous Overweight Current Overweight	Get Alert
Feb 26, 2025	JAZZJazz Pharmaceuticals	$208.43	-28.03%	Charles DuncanCantor Fitzgerald 68%	140 150	Previous Overweight Current Neutral	Get Alert
Feb 26, 2025	JAZZJazz Pharmaceuticals	$208.43	-15.56%	David AmsellemPiper Sandler 79%	163 176	Previous Overweight Current Overweight	Get Alert
Feb 26, 2025	JAZZJazz Pharmaceuticals	$208.43	-14.6%	Gregory RenzaRBC Capital 61%	178 179	Previous Outperform Current Outperform	Get Alert
Feb 26, 2025	JAZZJazz Pharmaceuticals	$208.43	0.27%	Jessica FyeJP Morgan 64%	200 209	Previous Overweight Current Overweight	Get Alert
Feb 26, 2025	JAZZJazz Pharmaceuticals	$208.43	0.75%	Ami FadiaNeedham 73%	205 210	Previous Buy Current Buy	Get Alert
Feb 13, 2025	JAZZJazz Pharmaceuticals	$208.43	-18.44%	Mohit BansalWells Fargo 71%	130 170	Previous Equal-Weight Current Overweight	Get Alert
Dec 12, 2024	JAZZJazz Pharmaceuticals	$208.43	-21.8%	David AmsellemPiper Sandler 79%	163 163	Previous Overweight Current Overweight	Get Alert
Dec 12, 2024	JAZZJazz Pharmaceuticals	$208.43	-14.12%	Gregory RenzaRBC Capital 61%	179 179	Previous Outperform Current Outperform	Get Alert
Dec 12, 2024	JAZZJazz Pharmaceuticals	$208.43	-0.69%	Ami FadiaNeedham 73%	207 207	Previous Buy Current Buy	Get Alert
Dec 10, 2024	JAZZJazz Pharmaceuticals	$208.43	-14.12%	Gregory RenzaRBC Capital 61%	179 179	Previous Outperform Current Outperform	Get Alert
Nov 22, 2024	JAZZJazz Pharmaceuticals	$208.43	-4.04%	Oren LivnatHC Wainwright & Co. 74%	200 200	Previous Buy Current Buy	Get Alert
Nov 21, 2024	JAZZJazz Pharmaceuticals	$208.43	-0.69%	Ami FadiaNeedham 73%	207 207	Previous Buy Current Buy	Get Alert
Nov 21, 2024	JAZZJazz Pharmaceuticals	$208.43	-21.8%	David AmsellemPiper Sandler 79%	163 166	Previous Overweight Current Overweight	Get Alert
Nov 18, 2024	JAZZJazz Pharmaceuticals	$208.43	-22.28%	Joel BeattyBaird 75%	154 162	Previous Outperform Current Outperform	Get Alert
Nov 7, 2024	JAZZJazz Pharmaceuticals	$208.43	-6.44%	—	195 200	Previous Buy Current Buy	Get Alert
Nov 7, 2024	JAZZJazz Pharmaceuticals	$208.43	-0.69%	Ami FadiaNeedham 73%	207 207	Previous Buy Current Buy	Get Alert
Oct 23, 2024	JAZZJazz Pharmaceuticals	$208.43	-14.12%	Gregory RenzaRBC Capital 61%	175 179	Previous Outperform Current Outperform	Get Alert
Oct 4, 2024	JAZZJazz Pharmaceuticals	$208.43	-16.04%	Gregory RenzaRBC Capital 61%	174 175	Previous Outperform Current Outperform	Get Alert
Sep 10, 2024	JAZZJazz Pharmaceuticals	$208.43	-1.65%	Ami FadiaNeedham 73%	205 205	Previous Buy Current Buy	Get Alert
Sep 9, 2024	JAZZJazz Pharmaceuticals	$208.43	-32.83%	Charles DuncanCantor Fitzgerald 68%	140 140	Previous Overweight Current Overweight	Get Alert
Aug 19, 2024	JAZZJazz Pharmaceuticals	$208.43	-3.08%	Jessica FyeJP Morgan 64%	190 202	Previous Overweight Current Overweight	Get Alert

Recent Analyst Stock Rating News

PRO

Canaccord Genuity Maintains Buy on Etoro Group, Lowers Price Target to $47

Canaccord Genuity analyst Joseph Vafi maintains Etoro Group (NASDAQ:ETOR) with a Buy and lowers the price target from $53 to $47.

PRO

Jones Trading Maintains Buy on Dynex Cap, Lowers Price Target to $12.5

Jones Trading analyst Jason Weaver maintains Dynex Cap (NYSE:DX) with a Buy and lowers the price target from $14.75 to $12.5.

PRO

Scotiabank Maintains Sector Outperform on Whitecap Res, Raises Price Target to C$22

Scotiabank analyst Kevin Fisk maintains Whitecap Res (TSX:WCP) with a Sector Outperform and raises the price target from C$19 to C$22.

PRO

Scotiabank Maintains Sector Perform on Vermilion Energy, Raises Price Target to C$20

Scotiabank analyst Kevin Fisk maintains Vermilion Energy (TSX:VET) with a Sector Perform and raises the price target from C$17 to C$20.

PRO

Scotiabank Maintains Sector Perform on Trisura Group, Lowers Price Target to C$52

Scotiabank analyst Phil Hardie maintains Trisura Group (TSX:TSU) with a Sector Perform and lowers the price target from C$53 to C$52.

PRO

Scotiabank Maintains Sector Outperform on Tourmaline Oil, Lowers Price Target to C$73

Scotiabank analyst Chris MacCulloch maintains Tourmaline Oil (TSX:TOU) with a Sector Outperform and lowers the price target from C$76 to C$73.

PRO

Scotiabank Maintains Sector Outperform on Suncor Energy, Raises Price Target to C$123

Scotiabank analyst Kevin Fisk maintains Suncor Energy (TSX:SU) with a Sector Outperform and raises the price target from C$106 to C$123.

PRO

Scotiabank Maintains Sector Outperform on Spartan Delta, Raises Price Target to C$17.5

Scotiabank analyst Kevin Fisk maintains Spartan Delta (TSX:SDE) with a Sector Outperform and raises the price target from C$15.5 to C$17.5.

PRO

Scotiabank Maintains Sector Perform on PrairieSky Royalty, Raises Price Target to C$36

Scotiabank analyst Kevin Fisk maintains PrairieSky Royalty (TSX:PSK) with a Sector Perform and raises the price target from C$35 to C$36.

PRO

Scotiabank Maintains Sector Perform on Peyto Exploration & Dev, Lowers Price Target to C$27

Scotiabank analyst Chris MacCulloch maintains Peyto Exploration & Dev (TSX:PEY) with a Sector Perform and lowers the price target from C$28.5 to C$27.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

What Are Analyst Stock Ratings?

Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.

Analysts arrive at stock ratings after they research companies’ public financial statements, communicate with executives and customers and interact with companies in other ways.

Most analysts issue ratings 4 times a year, usually at 3-month intervals.

How to Use Analyst Ratings

As an investor or trader, you want to be able to use analyst ratings effectively. Here are steps you can take to understand how to synthesize all the information analysts report about a particular company and how to apply it to your own trades.

Step 1: Check Ratings History

In the short term, look to see whether analysts suggest an initiation, upgrade or downgrade for a particular stock. Understand how the rating changed compared to the previous rating and whether a price target gets announced or changed.

Sometimes the rating stays the same and only the price target changes, which could cause the stock to move in either direction, depending on the significance of the change between the 2 price targets.

Step 2: Check for Other News

In the short term, check to see how the stock reacts to positive or negative news. This will be an indication of the company’s outlook because analyst ratings usually come out after the company announces news (it’ll typically be earnings news).

Step 3: Look at the Sector for News

Check to see if other stocks in the sector also received similar ratings. This could indicate micro news, which refers to when the whole sector or specific company trades in a specific way due to news outside of one company.

Step 4: Look at the Note

If available, look over the analyst note itself. The beginning of the note has the main information of the rating and price target. Investors should also take a look at the summary of the note, which you can find in the first couple pages and give you a concrete overview of the company. This can help you get an understanding of how analysts arrived at their thesis on the stock.

An example of an analyst note. Source: Needham

Step 5: Make a Decision

After reviewing the analyst ratings (and whether the analyst proposes a change or initiation) and find the reason for that note. Make a decision based on the analyst thesis on the company. This should give you guidance on how to make your thesis. Analyst ratings are a good indication of what professionals believe the company or sector will do, helping you get a better understanding of the companies you’re interested in.

Analyst Rating Accuracy

Analyst ratings are not set in stone and nobody knows indefinitely what a stock will do. Therefore, analyst ratings should be taken as an educated guess made by professionals who carefully study the specific company and sector in question. It's not a surprise that the accuracy of each rating can vary by each individual analyst and specific ratings on companies.

In other words, there’s no hard number or percentage on how accurate analyst ratings are because they are like educated guesses on what they think the stock will do based on their research, within that particular sector. In addition, each firm has so many analysts and so many different companies to review that you can compare ratings to glean what you believe is the truth.

Where Analyst Ratings Come From

Analyst ratings come from stock analysts. Analysts “go deep” on companies within a particular industry or sector. Some analysts employ a top-down approach (they start with an industry or sector and look for excellent companies within that industry or sector) and other stock analysts choose a bottom-up approach, which means they start with the company first and connect the dots within that company’s sector or industry. Analysts evaluate:

Financial statements
Economic fundamentals
Suppliers, customers and competitors
Management quality
Business model
Revenue
Expenses
Assets
Liabilities

While these evaluations are done using facts and figures that any investor can access, they come down to a conclusion the analyst must draw. While this isn’t an unqualified opinion, analysts will disagree because their interpretations of the data could vary.

Types of Stock Ratings

Stock ratings can range from simple “buy” and “sell” ratings to “equal weight” and “outperform” ratings. Here’s a quick overview of how analysts rate stocks.

Buy Rating

A “buy” rating indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and recommends that traders purchase the stock. An analyst may even go so far as to indicate that a stock is a “strong buy.” At the same time, you may choose to swing trade the asset for a profit and come back later to start the process all over again.

Sell Rating

A “sell” rating means that an analyst believes the stock will trend downward in a particular time frame. Analysts might even refer to a security as a “strong sell.” Remember, though, you may want to swing trade and come back to this asset in the future even though you just chose to sell, just as you would under a “buy” rating.

Hold

A “hold” rating suggests that investors should not buy more of or sell the specified stock because they believe the stock should perform in a way that’s consistent with the market or will perform similarly to comparable companies within that particular sector. This is akin to the value investing approach that Warren Buffett uses, looking to gain long-term value from a single stock rather than flipping it because of a bad week. As many have said, it’s not a loss until you sell.

Underperform

An “underperform” rating means an analyst indicates that a stock is expected to perform below the market or sector average. And yes, while the underperform rating may not bode well for an asset in the next few weeks, it may not stay that way. Continue to carefully monitor your portfolio to ensure that an underperforming asset hasn’t turned itself around. As companies are faced with the Herculean task of pleasing shareholders, they will push to fix their underperforming stocks, meaning that a stock you wrote off could rise again.

Outperform

An “outperform” rating means that an analyst expects a stock to outperform the market or sector average. While the stock may look to outperform the market or a sector’s average, that doesn’t mean it will continue to soar forever. You must look at an outperform rating as what that asset will do in recent times, but it may not maintain that trajectory.

Equal-Weight

An equal weight rating means that an analyst believes that an individual stock's performance will tie to the average of all the stocks that an analyst covers in that particular sector. This type of rating helps investors get a true comparison of stocks to each other within a particular sector or industry. At the same time, equal-weight ratings could change at any time.

Price Target

A price target is an analyst’s projection of a stock’s future price. A price target is generally set up in a general trade or area where the asset might land. This means that the analyst could get close without hitting the figure on the head. Even so, the analyst wants to get close and better predict the movement of the marketplace and the asset.

Understanding Stock Ratings

Stock ratings are assessments of the investment potential of a particular stock. They are typically created by financial analysts who evaluate a company's financial performance, competitive positioning, and market outlook to provide guidance on the stock's expected future performance.

Ratings typically range from "buy" to "sell," with variations in between, such as "hold," "accumulate," or "neutral." A "buy" rating suggests that the stock is likely to perform well in the future, and investors should consider purchasing it. Conversely, a "sell" rating indicates that the stock is expected to underperform, and investors should consider selling it.

It's important to note that ratings are not guarantees of performance and should not be relied upon solely when making investment decisions. Ratings are just one factor to consider when evaluating a stock's potential, and investors should also conduct their own research and analysis to make informed decisions.

Another thing to keep in mind is that different analysts may have different opinions on a stock, so it's a good idea to consider multiple ratings before making an investment decision.

In addition to analyst ratings, investors can also consider other factors when evaluating a stock, such as its financial statements, management team, industry trends, and overall market conditions. By combining all of these factors, investors can make informed decisions about which stocks to buy or sell.

In summary, stock ratings are an important tool for investors to consider when evaluating a stock's potential, but they should not be the only factor used in investment decision-making. It's important to conduct your own research, consider multiple ratings, and take into account other factors before making an investment decision.

Should You Use Analyst Ratings to Inform Your Own Trades?

You can definitely use analyst ratings to inform your own trades and inform your own thesis but it’s a good idea to do your own research. However, analyst ratings are just one step in what should be a much larger investment strategy. Don’t fall in love with just one analyst. Compare notes. Look into how these ratings match with activity on the market and current events. Plus, remember that an analyst rating could easily be incorrect. No one is perfect, but these ratings are a good place to start.

Visit Benzinga News for more guidance on how to research companies and make decisions about research, trading and investing.

Compare Online Stock Brokers

Claim Exclusive Offers

Interactive Brokers Review
Good Fit For:
Active and Global Traders
VIEW PROS & CONS:
Securely through Interactive Brokers’ website
Plus500 Review
Good Fit For:
Leveraged Trading
VIEW PROS & CONS:
securely through Plus500 Yield's website
public.com Review
Good Fit For:
Trading Ideas
VIEW PROS & CONS:
securely through public.com's website
Robinhood Review
Good Fit For:
Commission-Free Mobile Trading
VIEW PROS & CONS:
securely through Robinhood's website
TradeZero Review
Good Fit For:
Active Short Sellers
VIEW PROS & CONS:
securely through TradeZero [SPONSORED]'s website